[{"id":"870aa9ff-b88c-46cc-bea2-bf4b4460d70f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03002103","created_at":"2021-01-18T14:46:03.678Z","updated_at":"2024-07-02T16:35:49.514Z","phase":"Phase 3","brief_title":"A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT03002103","lead_sponsor":"SynCore Biotechnology Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • EndoTAG-1 (paclitaxel liposomal)"],"overall_status":"Suspended","enrollment":" Enrollment 420","initiation":"Initiation: 11/23/2016","start_date":" 11/23/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-04-26"}]